Drug intelligence / Profile preview

AG-2411

Development stage: Preclinical
Lead developer: AHN-GOOK PHARMACEUTICAL
Modality: Small Molecules
Administration: Subcutaneous

Overview

AG-2411 is a generic drug candidate currently under development by Ahn-Gook Pharmaceuticals. It is specifically categorized as a generic medicine intended for the treatment of cardiovascular diseases. As of early 2024, the project is in the research stage, focusing on the development of a generic alternative to an existing reference drug. While the specific active ingredient and the reference listed drug (RLD) have not been publicly disclosed in the company's high-level pipeline summaries, AG-2411 represents part of Ahn-Gook's strategic expansion within the cardiovascular therapeutic area.

Beyond the preview

Go deeper on AG-2411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-2411.

Explore the full profile